Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaIoana Agache, Marek Jutel, Carlos Canelo‐Aybar et al.|Allergy|2020Cited by 406
EAACI Biologicals Guidelines—Recommendations for severe asthmaIoana Agache, Marek Jutel, Cezmi A. Akdiş et al.|Allergy|2020Cited by 275